Zobrazeno 1 - 10
of 20
pro vyhledávání: ''
Autor:
Armaou, S.1, Pertesi, M.1, Fostira, F.1, Thodi, G.1, Athanasopoulos, P. S.1, Kamakari, S.2, Athanasiou, A.3, Gogas, H.4, Yannoukakos, D.1, Fountzilas, G.5,6, Konstantopoulou, I.1 reena@rrp.demokritos.gr
Publikováno v:
British Journal of Cancer. 7/7/2009, Vol. 101 Issue 1, p32-37. 6p. 2 Charts, 1 Graph.
Publikováno v:
British Journal of Cancer. 10/31/2005, Vol. 93 Issue 9, p973-976. 4p.
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Autor:
Geller, Melissa A., Cooley, Sarah, Argenta, Peter A., Downs, Levi S., Carson, Linda F., Judson, Patricia L., Ghebre, Rahel, Weigel, Brenda, Panoskaltsis-Mortari, Angela, Curtsinger, Julie, Miller, Jeffrey S.
Publikováno v:
Cancer Immunology, Immunotherapy; Dec2010, Vol. 59 Issue 12, p1877-1884, 8p
Publikováno v:
British Journal of Cancer
This study sought to examine changes in psychological distress following cancer genetic counselling. Women attending a family cancer clinic completed questionnaires before their appointment and at 2 weeks, 6 months and 12 months after their appointme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e408bb98c755ca3e0a4394f3ca58f04
https://openaccess.sgul.ac.uk/id/eprint/1639/1/86-6600030a.pdf
https://openaccess.sgul.ac.uk/id/eprint/1639/1/86-6600030a.pdf
Autor:
Jan Steffen, Michalina Dabrowska, Aneta Balabas, Magdalena Piatkowska, Dorota Nowakowska, Izabela Brozek, Anna Niwińska, Magdalena Ratajska, Jadwiga Rachtan, Janusz Limon, Anna Kluska
Publikováno v:
Familial Cancer
It is estimated that about 5–10% of ovarian and 2–5% of all breast cancer patients are carriers of a germline BRCA1 or BRCA2 gene mutation. Most families with detected BRCA1 or BRCA2 gene mutation are qualified for molecular testing on the basis
Publikováno v:
BMC Cancer
Background In the past decades, mortality of female gender related cancers declined in Switzerland and other developed countries. Differences in the decrease and in spatial patterns within Switzerland have been reported according to urbanisation and
Autor:
Riikka Nurminen, Johanna Schleutker, Heli Nevanlinna, Liisa M. Pelttari, Lauri A. Aaltonen, Alexandra E. Gylfe
Publikováno v:
BMC Cancer, Vol 12, Iss 1, p 552 (2012)
BMC Cancer
BMC Cancer
Background Rare, heterozygous germline mutations in the RAD51C gene have been found in breast and ovarian cancer families. In the Finnish population, we have identified two founder mutations in RAD51C that increase the risk of ovarian cancer but not
Publikováno v:
Breast Cancer Research
Introduction Mutations in BRCA1, BRCA2, ATM, TP53, CHK2 and PTEN account for many, but not all, multiple-case breast and ovarian cancer families. The histone acetyltransferase gene EP300 may function as a tumour suppressor gene because it is sometime
Autor:
Dagnija Kalniete, Jekaterina Zestkova, Arvids Irmejs, Janis Gardovskis, Karina Aksenoka, Andris Gardovskis, Dace Berzina, Miki Nakazawa-Miklasevica, Edvins Miklasevics
Publikováno v:
BMC Medical Genetics
Background The estimated ratio of hereditary breast/ovarian cancer (HBOC) based on family history is 1.5% in Latvia. This is significantly lower than the European average of 5–10%. Molecular markers like mutations and SNPs can help distinguish HBOC